Ask Our Experts The Evolving Landscape of Cancer Vaccines July 29, 2026 References Zaidi N, Jaffee EM, Yarchoan M. Recent advances in therapeutic cancer vaccines. Nature Reviews Cancer. 2025;25:517–533.https://doi.org/10.1038/s41568-025-00820-z Haanen JB, Schumacher TNM, Kagan JC, Fritsch EF, Wu CJ. Clinical development of cancer vaccines. Nature Medicine. 2026;32:828–840.https://doi.org/10.1038/s41591-026-04241-9 Ott PA. The promises and challenges of neoantigen cancer vaccines. Nature Biotechnology. 2026;44:740–751.https://doi.org/10.1038/s41587-026-03018-2 Wells DK, van Buuren MM, Dang KK, et al.; Tumor Neoantigen Selection Alliance. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020;183(3):818–834.e13.https://doi.org/10.1016/j.cell.2020.09.015 Khattak A, Carlino MS, Meniawy T, et al. Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomized phase IIb KEYNOTE-942 study. Journal of Clinical Oncology. Published online 2026.https://doi.org/10.1200/JCO-26-00835 ClinicalTrials.gov. A clinical study of intismeran autogene (V940) plus pembrolizumab in people with high-risk melanoma (V940-001; INTerpath-001). ClinicalTrials.gov identifier: NCT05933577.https://clinicaltrials.gov/study/NCT05933577 Sethna Z, Guasp P, Reiche C, et al. RNA neoantigen vaccines prime long-lived CD8-positive T cells in pancreatic cancer. Nature. 2025;639:1042–1051.https://doi.org/10.1038/s41586-024-08508-4 Latzer P, Zelba H, Battke F, et al. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nature Communications. 2024;15:6870.https://doi.org/10.1038/s41467-024-51315-8 Wainberg ZA, Weekes CD, Furqan M, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine. 2025;31:3648–3653.https://doi.org/10.1038/s41591-025-03876-4 Ahluwalia MS, Reardon DA, Abad AP, et al. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma. Journal of Clinical Oncology. 2023;41(7):1453–1465.https://doi.org/10.1200/JCO.22.00996 D’Alise AM, Willis J, Duzagac F, et al. Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. Nature Medicine. 2026;32:1002–1011.https://doi.org/10.1038/s41591-025-04182-9 U.S. Food and Drug Administration. For physicians: how to request single-patient expanded access (“compassionate use”).https://www.fda.gov/drugs/investigational-new-drug-ind-application/physicians-how-request-single-patient-expanded-access-compassionate-use Ghannam JY, Kovarsky D, Marrah L, et al. A personalized neoantigen vaccine to reprogram the immune landscape of glioblastoma. Journal of Clinical Oncology. 2026;44(suppl 16):2006. Conference abstract.https://doi.org/10.1200/JCO.2026.44.16_suppl.2006 Pages: 1 2 See More New Stories
